--- canonical_name: Naringenin alternate_names: 4',5,7-Trihydroxyflavanone, Naringetol, 5,7-Dihydroxy-2-(4-hydroxyphenyl)chroman-4-one canonical_topic: Naringenin for Health & Longevity short_topic_lc: naringenin creation_date: 2026-0814-1014 creator_ai_fullname: Grok 4 --- # Naringenin for Health & Longevity

Evidence Review created on 08/14/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Grok 4 **Also known as:** 4',5,7-Trihydroxyflavanone, Naringetol, 5,7-Dihydroxy-2-(4-hydroxyphenyl)chroman-4-one ## Motivation Naringenin is a bitter compound found in citrus fruit, the sugar-free form of grapefruit naringin. It is eaten in grapefruit, oranges, and tomatoes and is sold as a short-acting oral extract. Longevity-oriented adults meet it as a candidate metabolic compound that turns on the same cellular energy switch studied with metformin and that can lengthen life in laboratory worms. Bitter citrus peel has a long food-medicine history. Isolated naringenin later became a laboratory tool after grapefruit-juice drug interactions were mapped and after rodent work showed less liver fat and less diet-driven weight gain without a cut in calories. Human trials of the isolated compound remain few and brief. This review examines what naringenin is, how it is absorbed and cleared in the gut and liver, the human and laboratory record for blood fats, liver fat, and aging biology, and the practical limits set by medicine handling, channels that help the heart reset between beats, product quality, and monitoring. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading High-level overviews of naringenin from expert platforms and narrative reviews. - [Naringenin, a citrus fruit flavonoid, preserves muscle mass in aging while enhancing exercise capacity and aerobic metabolism efficiency (animal study)](https://www.foundmyfitness.com/stories/7fn5rk) - Rhonda Patrick Science Digest of mouse work on Sp1 (a muscle transcription factor) and ERRγ (estrogen-related receptor gamma): more oxidative fibers, run distance, and grip. - [Plant Flavonoid Naringenin Is a Senotherapeutic](https://www.lifespan.io/news/plant-flavonoid-naringenin-is-a-senotherapeutic/) - Steve Hill Lifespan.io write-up of mouse work on naringenin as a senotherapeutic (a compound aimed at worn-out cells) that quiets inflammatory signaling from aged brain cells. - [Bioflavonoid prevents metabolic syndrome and obesity in mice](https://www.lifeextension.com/newsletter/2009/7/bioflavonoid-prevents-metabolic-syndrome-and-obesity-in-mice) - Life Extension Contemporary write-up of the Huff *Ldlr*−/− (low-density lipoprotein [LDL] receptor knockout) mouse study in which dietary naringenin blocked Western-diet weight gain and insulin resistance without lowering calories. - [Metformin-like antidiabetic, cardio-protective and non-glycemic effects of naringenin: Molecular and pharmacological insights](https://pubmed.ncbi.nlm.nih.gov/28322845/) - Nyane et al., 2017 Narrative review comparing naringenin with metformin through AMP-activated protein kinase (AMPK; the cell's energy-sensing enzyme) and non-glucose actions. - [Citrus Flavonoids as Regulators of Lipoprotein Metabolism and Atherosclerosis](https://pubmed.ncbi.nlm.nih.gov/27146015/) - Mulvihill et al., 2016 The Huff-group synthesis of naringenin, hesperetin, and polymethoxyflavones on hepatic fat oxidation, apoB (apolipoprotein B) lipoproteins, and atherosclerosis in models. No dedicated naringenin episode or article was found from Andrew Huberman or Chris Kresser. Those platforms discuss related flavonoids (for example apigenin) or citrus foods without treating naringenin in depth. ## Grokipedia - [Naringenin](https://grokipedia.com/page/Naringenin) Dedicated Grokipedia entry covering chemistry, food sources, metabolism of the glycoside naringin, and the main proposed biologic actions. ## Examine - [Naringenin](https://examine.com/supplements/naringenin/) Examine's compound page: food sources, mostly preclinical antioxidant and cardiometabolic claims, and a feed entry on the 4-week fatty-liver trial. ## ConsumerLab No ConsumerLab article dedicated to naringenin was found. ## Systematic Reviews PubMed systematic reviews and meta-analyses that treat naringenin as the intervention, plus one network meta-analysis that ranks it among dietary polyphenols. - [A Comprehensive Systematic Review of the Effects of Naringenin, a Citrus-Derived Flavonoid, on Risk Factors for Nonalcoholic Fatty Liver Disease](https://pubmed.ncbi.nlm.nih.gov/32879962/) - Naeini et al., 2021 PRISMA (systematic-review reporting standard) review of 36 mostly preclinical papers on energy, lipids, glucose, inflammation, and oxidative stress before the later human fatty-liver trial. - [Efficacy of dietary polyphenol supplement in patients with non-alcoholic fatty liver disease: a network meta-analysis](https://pubmed.ncbi.nlm.nih.gov/40416369/) - Wang et al., 2025 Network meta-analysis of 54 human randomized controlled trials (RCTs; chance-assigned trials): naringenin ranked first for triglycerides and total cholesterol. - [The effect of immunomodulatory properties of naringenin on the inhibition of inflammation and oxidative stress in autoimmune disease models: a systematic review and meta-analysis of preclinical evidence](https://pubmed.ncbi.nlm.nih.gov/35804246/) - Alimohammadi et al., 2022 Preclinical meta-analysis: lower inflammatory cytokines and nuclear factor kappa B (NF-κB; a master inflammation switch), and higher glutathione enzymes. - [Naringenin induces intrinsic and extrinsic apoptotic signaling pathways in cancer cells: A systematic review and meta-analysis of in vitro and in vivo data](https://pubmed.ncbi.nlm.nih.gov/35797732/) - Faramarzi et al., 2022 Pooled cell and animal data showing higher caspase-3, -8, and -9 activity and Bax; no human cancer outcome trials. - [Antidepressant effects and therapeutic potential of naringenin: a systematic review and meta-analysis of preclinical studies](https://pubmed.ncbi.nlm.nih.gov/42422079/) - Huang et al., 2026 Thirteen rat studies: shorter immobility, more sucrose intake, lower inflammatory cytokines, and higher brain-derived neurotrophic factor; no human depression trials. No systematic review or meta-analysis of isolated naringenin's drug-interaction or QT-interval (heart-repolarization time) risk was found on PubMed as of 14 August 2026. ## Mechanism of Action Naringenin is absorbed mainly after gut bacteria remove the sugar from naringin. The free flavanone is then rapidly tagged by UDP-glucuronosyltransferase enzymes (UGTs; conjugation enzymes that mark molecules for excretion) in the gut and liver, so most circulating naringenin is a glucuronide or sulfate, not the parent compound. In cells it activates AMPK and sirtuin 1 (SIRT1; a deacetylase tied to mitochondrial and vessel maintenance). It also engages peroxisome proliferator-activated receptors alpha and gamma (PPAR-α and PPAR-γ; nuclear receptors that steer fat burning and insulin response). In primary human fat cells this raises uncoupling protein 1 and carnitine palmitoyltransferase 1β and increases oxygen use. Anti-inflammatory actions include damping NF-κB. A competing account treats naringenin as a weak phytoestrogen at estrogen receptor alpha and beta. Some cholesterol-homeostasis effects in liver cells are only partly estrogen-receptor dependent. Another competing account holds that most grapefruit-juice drug interactions come from furanocoumarins, not naringenin, although naringenin still inhibits cytochrome P450 3A4 (CYP3A4; a major drug-metabolizing enzyme) and organic anion-transporting polypeptides (OATPs; uptake transporters) in laboratory systems. Key properties: oral half-life about 2.7–3.0 hours; peak serum at 2–3 hours; dose-proportional exposure from 150 to 900 mg; extensive first-pass conjugation; human tissue-distribution data are sparse (animal work points to liver and intestine, with some brain exposure); clearance is driven by UGTs rather than a single CYP. It is multi-target, not a selective receptor ligand. ## Historical Context & Evolution Bitter citrus peel and fruit appear in East Asian and Mediterranean food-medicine as digestive and "cooling" materials. Chemists isolated naringin from grapefruit in the early twentieth century and identified naringenin as its aglycone (sugar-free form). Food use long predates any longevity claim. In the 1990s, grapefruit juice was shown to raise blood levels of several medicines. Naringenin was first proposed as the CYP3A4 blocker. A human excretion study then found that naringin is cleaved to naringenin by gut bacteria, but circulating free naringenin was low, which argued against naringenin as the main actor. Later work assigned most irreversible intestinal CYP3A4 loss to furanocoumarins such as bergamottin, while leaving naringenin a plausible OATP and modest CYP contributor. From the mid-2000s, the Huff laboratory reported that dietary naringenin prevented Western-diet obesity, dyslipidemia, and insulin resistance in *Ldlr*-null mice without reducing calorie intake ([Mulvihill et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19592617/)). That shifted naringenin from a grapefruit-interaction footnote to a metabolic candidate. A 2015 crossover trial of grapefruit juice versus a flavanone-free control linked juice flavanones to lower aortic stiffness in postmenopausal women ([Habauzit et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26016866/)). Pennington investigators then mapped single-dose safety and pharmacokinetics of an orange extract ([Rebello et al., 2020](https://pubmed.ncbi.nlm.nih.gov/31468636/)). A 4-week Iranian RCT of 200 mg/day isolated naringenin in fatty liver followed in 2021 ([Namkhah et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34516703/)). Worm and mouse aging papers (2021–2024) extended the story to lifespan and brain senescence. Current opinion is not a finished verdict: the metabolic mechanism is better specified than the human outcome record. ## Expected Benefits Human outcome evidence is a single 4-week fatty-liver RCT (reported in two papers), a grapefruit-juice vascular trial that is not isolated naringenin, a one-person metabolic case, and a single-dose pharmacokinetic study. No High-grade benefit is assigned. ### Medium 🟩 🟩 #### Improved Atherogenic Lipid Profile In overweight adults with nonalcoholic fatty liver disease (NAFLD; fat build-up in the liver not driven by heavy alcohol), 100 mg naringenin twice daily for 4 weeks lowered triglycerides, total cholesterol, and low-density lipoprotein (LDL; the cholesterol fraction that feeds arterial plaque) and raised high-density lipoprotein (HDL; the reverse-transport fraction) versus placebo ([Namkhah et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34516703/); [Naeini et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34860705/)). A 2025 network meta-analysis ranked naringenin first for triglycerides and total cholesterol among dietary polyphenols, on this one small node ([Wang et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40416369/)). **Magnitude:** Versus placebo at 4 weeks, between-group differences include about −78 mg/dL triglycerides; cholesterol-fraction changes were statistically significant in the same trial. ### Low 🟩 #### Reduced Hepatic Steatosis Grade The same 44-person RCT reported fewer high ultrasound NAFLD grades after 200 mg/day for 4 weeks, without a fall in alanine or aspartate aminotransferase (ALT, AST; liver-injury enzymes) or the fibrosis score ([Namkhah et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34516703/)). Grade mix shifted; fat fraction was not quantified. **Magnitude:** Ultrasound grade distribution improved versus placebo at 4 weeks; aminotransferases and fibrosis score did not change. The literature report no outcome figure for the grade shift. #### Lower Body Mass and Visceral Fat The companion RCT paper reported lower body-mass index (BMI; weight relative to height) and visceral fat versus placebo at 4 weeks ([Naeini et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34860705/)). An 8-week case at 150 mg three times daily lost 2.3 kg ([Murugesan et al., 2020](https://pubmed.ncbi.nlm.nih.gov/31670603/)). **Magnitude:** BMI and visceral fat fell versus placebo at 4 weeks; the literature report no outcome figure for the size of those changes. The case lost 2.3 kg over 8 weeks. #### Lower Central Arterial Stiffness (Juice Flavanones) A 6-month randomized crossover in 48 healthy postmenopausal women compared 340 mL grapefruit juice providing 210 mg naringenin glycosides with a matched flavanone-free drink ([Habauzit et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26016866/)). Pulse-wave velocity fell; dilation, blood pressure, and glucose did not. This is a juice-matrix result, not isolated naringenin. **Magnitude:** Pulse-wave velocity 7.36 ± 1.15 m/s after juice versus 7.70 ± 1.36 m/s after the control drink (treatment *P* = 0.019). ### Speculative 🟨 #### Higher Insulin Sensitivity and Acute Metabolic Rate Primary human fat cells increase oxygen use on naringenin. One uncontrolled case reported lower insulin and a brief metabolic-rate rise ([Murugesan et al., 2020](https://pubmed.ncbi.nlm.nih.gov/31670603/)); no controlled clamp trial exists. #### Longer Lifespan and Slower Brain Aging Naringenin extended *Caenorhabditis elegans* life and, at 100 mg/kg, raised brain SIRT1 activity in middle-aged mice ([Piragine et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38897393/)). Basis is animal and worm only. #### Less Vascular Senescence via SIRT1 In aged *Apoe*-null mice, naringenin reduced aortic senescence marks via SIRT1, FOXO3a (a stress-resistance factor), and PGC-1α (a mitochondrial coactivator) ([Wang et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37343148/)). Basis is animal and cell only. #### Greater Muscle Endurance in Aging Mouse work identified Sp1 as a direct naringenin target and reported more oxidative fibers, longer run distance, and better grip in adult, middle-aged, and dystrophic mice ([Lv et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37874675/)). No human muscle RCT exists. #### Lower Cancer-Cell Viability A preclinical meta-analysis found higher caspase-driven apoptosis in cancer cells and tumor-bearing animals ([Faramarzi et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35797732/)). No isolated-naringenin cancer-outcome trial in humans is available. #### Lower Inflammatory and Oxidative-Stress Markers A preclinical meta-analysis found lower inflammatory cytokines and NF-κB activity and higher glutathione enzymes in autoimmune models ([Alimohammadi et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35804246/)). Basis is animal and cell only. #### Lower Depression-Like Behavior in Animals A preclinical meta-analysis of thirteen rat studies found shorter immobility, more sucrose intake, and higher brain-derived neurotrophic factor ([Huang et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42422079/)). Basis is animal only; no human depression trial exists. ## Benefit-Modifying Factors - **UGT and microbiome handling:** First-pass glucuronidation and the need for bacterial cleavage of naringin create large person-to-person differences in free naringenin exposure. - **Baseline liver fat and lipids:** The only positive human lipid and steatosis signal is in overweight adults with ultrasound NAFLD; lean people with normal lipids have no outcome trial. - **Sex:** The juice-stiffness trial enrolled only postmenopausal women. The fatty-liver RCT was mixed-sex and not powered for a sex split. Estrogen-receptor binding makes a sex difference biologically plausible and untested. - **Pre-existing metabolic disease:** Insulin-resistant, fatty-liver, and dyslipidemic phenotypes are the groups in which rodent and the one human RCT show movement; euglycemic athletes are unstudied. - **Age:** Mouse muscle and brain-aging work used middle-aged animals. Human RCTs enrolled middle-aged adults, not people over 75. ## Potential Risks & Side Effects Single oral doses of 150–900 mg in healthy adults produced no relevant adverse events or safety-lab shifts. The risk record is driven by transporter/CYP overlap with grapefruit, a laboratory block of a cardiac potassium channel, and weak estrogen-receptor binding—not by a dense post-marketing file. ### Medium 🟥 🟥 #### Altered Exposure of CYP3A4 and OATP Substrate Drugs ⚠️ Conflicted Naringenin inhibits CYP3A4, other CYPs, P-glycoprotein (P-gp; an efflux pump that pushes drugs out of cells), and OATPs in vitro. Grapefruit juice raises levels of many of those drugs. Human work after juice shows naringin becomes naringenin, but free naringenin is often too low to explain the classic CYP3A4 interaction; furanocoumarins account for most irreversible gut CYP3A4 loss ([Fuhr & Kummert, 1995](https://pubmed.ncbi.nlm.nih.gov/7586927/); [Bailey et al., 2000](https://pubmed.ncbi.nlm.nih.gov/11103749/)). Isolated orange-extract naringenin has not reproduced juice-level interactions. Direction is inhibition of clearance or uptake; size versus juice is the conflict. **Magnitude:** Isolated-naringenin interaction size is not quantified in a dedicated clinical drug-interaction trial; juice can raise sensitive CYP3A4-substrate exposure several-fold, a figure that cannot be copied onto 200–600 mg naringenin. ### Low 🟥 #### QTc Interval (heart-repolarization time) Prolongation at High Exposure Naringenin blocked the hERG channel (the potassium channel ending the cardiac action potential) at 36.5 μmol/L. Grapefruit juice prolonged the QTc interval (heart-repolarization time on an electrocardiogram) by 12.5 ms ([Zitron et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15710766/)). A 600 mg dose peaked at 48 μmol/L ([Rebello et al., 2020](https://pubmed.ncbi.nlm.nih.gov/31468636/)). **Magnitude:** +12.5 ms peak QTc after 1 L grapefruit juice; isolated-naringenin QTc change is not quantified. ### Speculative 🟨 #### Weak Estrogen-Receptor Activity Naringenin binds estrogen receptor alpha and beta in cells, with mixed tissue direction ([Pallottini et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36555447/)). No controlled human hormone-outcome trial exists. #### Uncharacterized Long-Term High-Dose Toxicity Repeat-dose human data stop at 4–8 weeks and at 200–450 mg/day. Chronic high-dose organ toxicity is inferred from the short record and animal work, not from a long human series. #### Blunting of Exercise-Induced Redox Adaptation As a redox-active flavonoid, high-dose naringenin could in principle damp the reactive-oxygen signal that helps endurance training adapt. This is mechanistic only; no human training study tested it. ## Risk-Modifying Factors - **CYP3A4, OATP, and UGT variants:** People with low baseline CYP3A4 or UGT1A1 (the main bilirubin-conjugating enzyme) activity, or on strong inhibitors, may see larger swings in either naringenin or companion drugs. - **Baseline QTc and electrolytes:** A longer starting QTc, low potassium or magnesium, or other hERG blockers raise the theoretical arrhythmia stake at high peak levels. - **Sex and estrogen status:** Premenopausal versus postmenopausal status may change both lipid benefit and estrogen-receptor tone; this is untested in a naringenin RCT. - **Cirrhosis, advanced kidney disease, and citrus allergy:** These were exclusion criteria in the pharmacokinetic and fatty-liver work; first-pass failure would raise exposure. - **Older age:** Slower conjugation, more polypharmacy, and more baseline QTc-prolonging drugs concentrate risk after 70. ## Key Interactions & Contraindications - **CYP3A4 substrate medicines (simvastatin, atorvastatin, felodipine, buspirone, some benzodiazepines):** Caution. Juice can raise exposure; isolated naringenin is a weaker, less proven inhibitor. Avoid large same-time doses; monitor for statin muscle symptoms or excess sedation. - **OATP substrates (fexofenadine, some statins, aliskiren):** Caution. Naringenin can slow intestinal uptake and lower, or unpredictably change, levels. Separate dosing by several hours if both are used. - **P-gp substrates (digoxin, some direct oral anticoagulants (blood thinners taken by mouth)):** Monitor. In vitro P-gp block could raise levels; no dedicated naringenin–digoxin trial exists. - **QT-prolonging medicines (amiodarone, dofetilide, moxifloxacin, some antipsychotics, methadone):** Caution, possible additive hERG block. Isolated naringenin plus a class-III agent (a potassium-channel rhythm medicine) is untested; juice flavonoids have shown additive channel block in cells. - **Oral estrogens and tamoxifen:** Caution. Weak receptor binding plus possible reduced estrogen clearance with grapefruit-type mixtures. Isolated-naringenin hormone kinetics are unmeasured. - **Over-the-counter antihistamines (fexofenadine) and acetaminophen:** Monitor. Fexofenadine is an OATP probe; acetaminophen shares glucuronidation capacity. Clinical naringenin data are thin. - **Other flavonoids and berberine:** Caution. Additive AMPK and CYP/UGT traffic is plausible. Combined metabolic regimens raise interaction complexity without outcome trials. - **Metformin, berberine, and high-dose niacin:** Monitor. Potentiating on glucose and lipids is biologically plausible; hypoglycemia has not been reported with naringenin alone. **Populations who should avoid naringenin:** - People on narrow-therapeutic-index CYP3A4 or OATP drugs (tacrolimus, cyclosporine, some antiarrhythmics) unless a clinician is tracking drug levels - Congenital long-QT syndromes, baseline QTc above about 450–470 ms, or combination QT-prolonging therapy - Known citrus-flavonoid allergy - Pregnancy and lactation (no adequate human reproductive data) - Decompensated cirrhosis (Child-Pugh C) or advanced kidney failure (eGFR (estimated filtration rate) <30 mL/min/1.73 m²), where first-pass and conjugation fail ## Risk Mitigation Strategies - **Medication reconciliation before the first dose:** Protocols typically start by listing CYP3A4, OATP, P-gp, and QT-prolonging drugs. This targets unexpected exposure swings and additive hERG block. - **Split doses at or below 300 mg:** Rebello data support 150–300 mg twice daily to stay near adipocyte-active micromolar levels without a 900 mg peak. This limits Cmax (peak blood concentration)-related hERG overlap. - **Time separation from interacting oral drugs:** Two to four hours from OATP and CYP3A4 substrates reduces same-window transporter competition. - **Electrolyte and QTc check if combining QT-prolonging drugs:** Potassium and magnesium in range, plus an electrocardiogram if other hERG blockers are present, address additive channel block. - **Short first exposure window:** A first 4-week window, then a repeat of lipids, ALT/AST, and symptoms, matches the only human outcome trial length. - **Grapefruit juice not used to raise exposure:** Juice adds furanocoumarins that isolated naringenin does not, and multiplies CYP3A4 risk. ## Therapeutic Protocol No professional society protocol exists. Two academic styles dominate: Pennington pharmacokinetic dosing and the Tehran 4-week fatty-liver regimen. - **Tehran fatty-liver regimen:** 100 mg isolated naringenin twice daily, before lunch and dinner, for 4 weeks, in overweight adults with ultrasound NAFLD. - **Pennington extract regimen:** Whole-orange extract standardized to naringenin; single doses 150–900 mg were safe; the investigators proposed 300 mg twice daily to reach ~8 μmol/L-effective exposure. - **Time of day:** With daytime meals. Half-life ~3 hours makes bedtime-only dosing a poor match to all-day AMPK tone and leaves a long overnight gap. - **Half-life and split dosing:** Apparent half-life 2.65–3.0 hours. A single daily dose is not supported by the concentration–time curve. - **Genetics:** No validated APOE, MTHFR, or COMT dosing rule (lipid-transport, folate, and catechol genes). Higher free levels in UGT1A1 poor conjugators remain untested as a dose key. - **Sex:** No sex-specific milligram rule. Postmenopausal women have juice-stiffness data; they do not have an isolated-naringenin dose finding. - **Age:** After 70, 150 mg twice daily is the low end of the studied human range, given polypharmacy and QTc. - **Baseline lipids and liver fat:** The outcome protocol was built for people with NAFLD and mixed dyslipidemia, not for already-optimal lipids. - **Pre-existing disease:** Decompensated liver or kidney disease and active hormone-sensitive cancer sit outside the studied human populations. ## Discontinuation & Cycling - **Duration intent:** Trials are 4–8 weeks. Nothing establishes a lifelong requirement. Metabolic effects would be expected to fade over days given the 3-hour half-life. - **Withdrawal:** No withdrawal syndrome is described. Safety labs did not rebound in a harmful direction after single doses. - **Taper:** Not required on pharmacokinetic grounds. People on interacting drugs can stop without a taper; the interacting drug's level may change within 1–3 days. - **Cycling:** No tolerance or receptor-downregulation cycle is established. Some practitioners run 4–12 weeks on, then reassess lipids, rather than an arbitrary week-on/week-off pattern. ## Sourcing and Quality - **Form:** Isolated naringenin (aglycone) is not the same as naringin, citrus bioflavonoid complexes, or grapefruit juice. Labels that only list "citrus bioflavonoids" do not guarantee a milligram dose of naringenin. - **Standardization:** HPLC (high-performance liquid chromatography)-stated naringenin content (for example the 28% orange extract used at Pennington) is the form used in the human pharmacokinetic work. Naringin-only products require bacterial conversion. - **Third-party testing:** USP, NSF, or ISO-accredited identity, heavy-metal, and microbial panels are the usual marks. ConsumerLab has no naringenin product review. - **Enhanced-delivery forms:** Phytosome (phospholipid-bound), cyclodextrin (sugar-ring carrier), and nanoparticle versions exist to fight poor solubility. Human comparative bioavailability versus the Pennington extract is mostly untested. - **Brands:** Life Extension Citrus Bioflavonoid Complex and similar mass-market citrus blends are mixed-flavonoid products, not isolated naringenin. Isolated capsules appear from smaller cGMP (current Good Manufacturing Practice) suppliers; verify a lot-specific assay. ## Practical Considerations - **Time to effect:** Lipid and steatosis changes were measured at 4 weeks. Peak serum is at 2–3 hours; any metabolic-rate rise in the case report peaked at 1 hour. - **Common pitfalls:** Treating grapefruit juice as equivalent to a capsule; buying naringin labeled as naringenin; combining with statins or QT-prolonging drugs without a plan; expecting ALT to fall when the trial showed grade change without enzyme change. - **Regulatory status:** Sold in the United States as a dietary supplement, not an FDA-approved drug. Food-level naringenin is a normal citrus constituent. Disease-treatment claims on labels exceed the evidence. - **Cost and access:** Isolated naringenin is uncommon next to citrus blends but not scarce. It is paid out of pocket; covered comparators such as metformin give payers little reason to fund trials. ## Interaction with Foundational Habits - **Sleep:** Direct effect unknown. The 3-hour half-life and daytime-meal protocol argue against a dedicated night dose. No trial reported insomnia or sedation. - **Nutrition:** Indirect and potentiating with a lower-refined-carbohydrate pattern that already lowers liver fat. Avoid using juice as the vehicle. Fat-containing meals may aid dissolution of this poorly soluble flavanone. - **Exercise:** Mouse data show more oxidative fibers and endurance (potentiating in animals). A theoretical blunting of training hormesis (the useful stress signal that helps the body adapt) at high antioxidant doses remains untested. No human timing-around-workouts study exists. - **Stress management:** Preclinical cuts in inflammatory cytokines and, in rats, depression-like behavior are indirect. No human cortisol or validated stress-scale trial of isolated naringenin was found. ## Monitoring Protocol & Defining Success Before the first dose, document the medication list (CYP3A4, OATP, P-gp, QT-prolonging agents), citrus allergy, and—if high-dose or QT-active drugs are present—a baseline electrocardiogram. Draw a fasting lipid panel, ALT, AST, fasting glucose and insulin, and high-sensitivity C-reactive protein (hs-CRP; a circulating inflammation marker). Repeat the same fasting blood panel at 4 weeks, then every 3–6 months if use continues. Recheck QTc after dose increases or when a new QT-active drug is added. Success in the only human outcome trial was a better lipid panel and a lower ultrasound steatosis grade at 4 weeks, not a fall in aminotransferases. The 4-week panel is the first check on whether those same endpoints moved. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | | --- | --- | --- | --- | | Fasting triglycerides | <100 mg/dL | Primary lipid signal in the NAFLD RCT | Conventional flag is often <150 mg/dL; 9–12 h fast | | LDL cholesterol | <70–100 mg/dL, individualized | Atherogenic fraction that moved in the RCT | Pair with non-HDL and apoB (apolipoprotein B) if available | | HDL cholesterol | >50 mg/dL (men), >60 mg/dL (women) | Rose versus placebo at 4 weeks | Fasting sample; not a stand-alone success marker | | ALT | <25–30 U/L (men), <19–25 U/L (women) | Safety and liver-fat context | Conventional upper limits ~40 U/L are higher; the RCT did not move ALT | | AST | <25–30 U/L | Safety companion to ALT | Interpret with ALT; isolated AST rise is not the naringenin signal | | Fasting insulin | 3–8 μIU/mL | Case-level insulin drop; metabolic context | Conventional labs often flag only >20–25 μIU/mL; 12 h fast | | Fasting glucose | 70–85 mg/dL | Metabolic context | Conventional <100 mg/dL; not shown to change clinically in the case | | hs-CRP | <1.0 mg/L | Inflammatory tone | Optional; no naringenin RCT used it as primary | | QTc (ECG) | <430 ms (men), <450 ms (women) | hERG overlap at high Cmax | ECG is electrocardiogram. Needed if QT-active drugs or doses ≥600 mg; not routine at 200 mg in healthy adults | Qualitative markers: - Afternoon energy and post-meal fullness - Training endurance and recovery (mouse signal, human unproven) - New muscle aches if a statin is co-used - Palpitations, syncope (fainting), or new-onset dizziness (stop and obtain an ECG) ## Emerging Research - **Bone-healing RCT (recruiting):** [NCT06612762](https://clinicaltrials.gov/study/NCT06612762) randomizes 70 adults after lower-limb fracture surgery to naringenin (500 mg/day for 14 days, then 250 mg/day to day 90) versus placebo; inflammatory markers and radiographic fusion are the endpoints. - **Completed PK (pharmacokinetic) map:** [NCT03582553](https://clinicaltrials.gov/study/NCT03582553) (Pennington; n = 18) is the published single-ascending-dose safety and concentration–time study behind the 150–900 mg human exposure data. - **Completed HCV (hepatitis C virus) pilot:** [NCT01091077](https://clinicaltrials.gov/study/NCT01091077) tested naringenin pharmacokinetics in seven people with hepatitis C; it is not an efficacy landmark. - **Worm-to-mammal aging:** [Piragine et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38897393/) lengthened *C. elegans* life and shifted mouse brain aging marks via SIRT1. A negative or null human cognitive trial would weaken the longevity case. - **Network ranking that could shrink:** [Wang et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40416369/) placed naringenin first for triglycerides among polyphenols. A second, larger lipid RCT that failed to replicate the Tehran effect would collapse that ranking. - **hERG additivity:** Cell work continues to show naringenin adding to quinidine- or dofetilide-type block ([Lin et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18057881/)). A dedicated thorough-QT study at 300–600 mg could raise or lower the cardiac caution. ## Conclusion Naringenin is a short-acting citrus compound taken in food or as an oral extract. The clearest human signal is a 4-week improvement in blood fats and ultrasound liver-fat grade in overweight adults with fatty liver, from one small academic trial. Single doses up to 900 milligrams did not disturb routine safety labs. Weight, insulin, and metabolic-rate claims rest on that short trial plus one case. Lifespan, vessel aging, and muscle-endurance claims rest on worms, mice, and cells. The practical constraint is not a pile of reported toxicities. It is overlap with grapefruit-type drug handling and, at high peak levels, a laboratory block of a channel that helps the heart reset between beats. Food-level juice and isolated naringenin are not interchangeable: other grapefruit compounds, not naringenin, drive most classic grapefruit–drug interactions, yet naringenin itself can still slow certain gut uptake pumps. Estrogen-receptor binding is weak and mixed in direction. The evidence base is thin for a longevity compound. One U.S. academic group mapped human blood levels; one Iranian group ran the 4-week fatty-liver trial. No drug-maker consensus and no insurer incentive shape the literature. For a risk-aware adult already working on liver fat, lipids, and a complex medicine list, naringenin is a poorly absorbed, multi-target citrus compound with a plausible metabolic mechanism and a still-narrow human record. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**